![](https://www.immupharma.co.uk/wp-content/uploads/2019/02/Ureka-Nature-Communications-Feb-2019-copy-1-350x230.jpg)
‘Nature Communications’ published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl (“Ureka”), ImmuPharma’s subsidiary.
![](https://www.immupharma.co.uk/wp-content/uploads/2017/08/autojnls-01091957-1.jpg)
Findings with the P140 peptide support a direct cross-talk between autophagy and certain central and peripheral neuronal diseases
![](https://www.immupharma.co.uk/wp-content/uploads/2008/12/10520192_ml-350x230.jpg)
Cancer compound IPP-204106 chosen to be on the cover of AACR disclosing the specific binding to nucleolin and therefore to tumour cells by the Nucants.
![](https://www.immupharma.co.uk/wp-content/uploads/2017/02/ThinkstockPhotos-533669199-350x230.jpg)
Special article “Resetting the autoreactive immune system with a therapeutic peptide in lupus” on autophagy
![](https://www.immupharma.co.uk/wp-content/uploads/2017/02/Portfolio_1-1-350x230.jpg)
New Opportunities for Therapy of Autoimmune Diseases: published in Genetics & Epigenetics outlinung the potential in other indications
![](https://www.immupharma.co.uk/wp-content/uploads/2017/02/ImmuPharma-Web-Graphics-39-350x230.jpg)
Publication of Lupuzor’s double blind phase IIb results in the Annals of the Rheumatic Diseases of the British Medical Journal
![](https://www.immupharma.co.uk/wp-content/uploads/2012/09/dna-1811955_960_720-350x230.jpg)
Publication in the Journal of Autoimmunity on Peptide-based approaches to treat lupus and other autoimmune diseases
![](https://www.immupharma.co.uk/wp-content/uploads/2017/02/ThinkstockPhotos-135343452-350x230.jpg)
Annals of the Rheumatic Diseases paper on mode of action of Lupuzor on HSC70+ antigen-presenting cells
![](https://www.immupharma.co.uk/wp-content/uploads/2009/04/centrifuge-350x230.jpg)
Publication in PLoS One – Lupuzor (P140) controls Lupus by interacting with the HSC70 protein and via a mechanism mediated by γδ T cells